Revenue: As of FY2026, the actual value is USD 8.26 M, missing the estimate of USD 9.045 M.EPS: As of FY2026, the actual value is USD -0.54, beating the estimate of USD -1.2444.EBIT: As of FY2026, the actual value is USD -693.18 M.<h4>Consolidated Financial Position</h4>As of March 31, 2026, Roivant Sciences Ltd. reported consolidated cash, cash equivalents, and marketable securities of $4.3 billion, with an accumulated deficit of approximately $501.8 million at the same date, supporting a cash runway into profitability.<h4>Share Repurchase Program</h4>For the twelve months ended March 31, 2026, Roivant Sciences Ltd. repurchased approximately 24.0 million common shares for an aggregate repurchase price of approximately $314.9 million.<h4>Patent Infringement Settlement</h4>Roivant Sciences Ltd. announced a $2.25 billion global settlement with Moderna, resolving patent-infringement litigation. Moderna is scheduled to pay Genevant and Arbutus $950 million in July 2026, with an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.<h4>Vant Ownership (as of March 31, 2026)</h4><ul><li>Priovant: Roivant Sciences Ltd. owned 72% on a basic ownership basis and 66% on a fully diluted basis.</li><li>Immunovant: Roivant Sciences Ltd. owned 56% on a basic ownership basis and 52% on a fully diluted basis.</li><li>Pulmovant: Roivant Sciences Ltd. owned 97% on a basic ownership basis and 90% on a fully diluted basis.</li><li>Genevant: Roivant Sciences Ltd. owned 83% on a basic ownership basis and 64% on a fully diluted basis.</li><li>Covant: Roivant Sciences Ltd. owned 94% on a basic ownership basis and 91% on a fully diluted basis.</li><li>Arbutus: Roivant Sciences Ltd. owned 20% on a basic ownership basis and 19% on a fully diluted basis.</li></ul><h4>Vant Milestone &amp; Royalty Payments (Summary of Select Potential Future Obligations)</h4><ul><li>Priovant / Pfizer: Potential mid-tens-of-millions sales milestone payment if aggregate net sales exceed a mid-hundreds-of-millions amount, along with tiered sub-teens royalty on net sales. Pfizer is also obligated to pay Priovant a low tens-of-millions milestone if its net sales outside Priovant’s territory exceed a mid-hundreds-of-millions amount, plus tiered high single-digit to sub-teens royalty on net sales outside Priovant’s territory.</li><li>Immunovant / HanAll: Up to an aggregate of $420.0 million in future contingent payments upon achievement of certain regulatory and sales milestone events, plus tiered royalties ranging from mid-single digits to mid-teens percentage of net sales of licensed products. Immunovant Sciences GmbH (ISG) previously paid an aggregate purchase price of $37.8 million to RSG in December 2018 for rights under the HanAll Agreement.</li><li>Pulmovant / Bayer: Up to an aggregate of $280 million upon achievement of certain development, regulatory, and net sales milestone events, plus tiered high-single-digits royalty on annual net sales of licensed products. Pulmovant made an initial payment of approximately $14 million to Bayer.</li><li>Genevant / Arbutus: Up to 20% of Royalty-Related Receipts from sublicenses or collaborations, or tiered low single-digit royalties on net sales by sublicensees. Arbutus is entitled to 20% of proceeds from patent infringement actions or tiered low single-digit royalties on net sales of the infringing product after deducting litigation costs.</li></ul><h4>Outlook / Guidance</h4>Roivant Sciences Ltd. anticipates ongoing announcements for new mid/late-stage in-licensing opportunities. The company expects an FDA decision on brepocitinib in dermatomyositis and its commercial launch by the end of September 2026. Topline data from various Phase 2 and Phase 3 trials for mosliciguat and IMVT-1402 are projected between the second half of 2026 and 2028.

Roivant Sciences | 10-K: FY2026 Revenue Misses Estimate at USD 8.26 M